PharmiWeb

The European Commission has Granted Orphan Medicinal Product Designation in the EU for MIV-818

STOCKHOLM, July 3, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the European Commission, in accordance with the opinion from the European Medicines Agency (EMA), has ...
Stockhouse

FDA Grants MIV-818 Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma

STOCKHOLM, May 6, 2020 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to MIV-818 for the ...
PharmiWeb

Medivir's Phase II Study of MIV-711 in Patients With Osteoarthritis Published in Annals of Internal Medicine

STOCKHOLM, Jan. 20, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announces that the phase II study of MIV-711 in patients with osteoarthritis has been published in the respected journal ...
Nasdaq

First Liver Cancer Patient Dosed in the MIV-818 Phase Ib Study

STOCKHOLM, March 10, 2020 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed in the phase Ib study of MIV-818. The MIV ...
Business Wire

Medivir Licenses Rights to MIV-802 to Trek Therapeutics

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (Nasdaq Stockholm: MVIR) and Trek Therapeutics (TREKtx) today announced that TREKtx has licensed the exclusive rights to develop and ...